神経刺激装置の世界市場2020-2026:装置別(脊髄刺激装置、脳深部刺激装置、仙骨神経刺激装置、迷走神経刺激装置、その他)、用途別、地域別

◆英語タイトル:Global Neurostimulation Devices Market By Devices (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators and Other Devices) By Applications (Pain Management, Hearing Loss, Urinary Incontinence, Parkinson's Disease, Epilepsy and Other Applications) By Region, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT049
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年5月31日
◆ページ数:205
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、イギリス、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、マレーシア、ブラジル、アルゼンチン、アラブ首長国連邦、サウジアラビア、南アフリカ、ナイジェリア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD3,600 ⇒換算¥388,800見積依頼/購入/質問フォーム
Global License(法人利用)USD6,048 ⇒換算¥653,184見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、神経刺激装置の世界市場について、市場範囲・調査手法、市場概要、競争分析、装置別(脊髄刺激装置、脳深部刺激装置、仙骨神経刺激装置、迷走神経刺激装置、その他)分析、用途別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・競争分析
・神経刺激装置の世界市場規模:装置別(脊髄刺激装置、脳深部刺激装置、仙骨神経刺激装置、迷走神経刺激装置、その他)
・神経刺激装置の世界市場規模:用途別
・神経刺激装置の世界市場規模:地域別
・企業概要
【レポートの概要】

The Global Neurostimulation Devices Market size is expected to reach $10.5 billion by 2026, rising at a market growth of 12.5% CAGR during the forecast period. Neuromodulation is a process that uses an implantable medical device to modulate and alter neural activity for therapeutic purposes. Neuromodulation equipment is called the neurostimulator that helps to treat neurological conditions that can provide an electric stimulus to the expected brain, nervous system, and spinal cord of the patient.

The central nervous systems (CNS) as well as the human peripheral nervous system (PNS) have affected neurological diseases such as Alzheimer’s, Parkinson’s, epilepsy, and cerebrovascular disease. The neurostimulation technique plays a vital role in the management of these neurological disorders. The electrodes in the devices generate mild electrical impulses to complement the neurological activity of the patients.

Among the many treatment options for overactive bladder symptoms is sacral nerve stimulation therapy (also known as sacral neuromodulation therapy). The treatment of overactive bladder with or without urine leakage and bladder vacuum can be done with sacral nerve stimulation therapy. In certain individuals who have not undergone more conservative treatments including drug therapy, the sacral nerve stimulation therapy is more suitable. Usually, a medication, behavioral therapy, and/or physical therapy must be completed before the sacral nerve stimulation therapy is taken into consideration.

Stimulation of the vagus nerve reduces seizures by transmitting normal, mild electrical energy through the vagus nerve into the brain. Often it is recognized as a “brain pacemaker.” A pacemaker is inserted into the chest under the skin. The vagus nerve of the neck is wound around a cable from the device.

Based on Devices, the market is segmented into Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators and Other Devices. Based on Applications, the market is segmented into Pain Management, Hearing Loss, Urinary Incontinence, Parkinson’s Disease, Epilepsy and Other Applications. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.
The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix, Abbott Laboratories, Medtronic PLC, and Boston Scientific Corporation are the forerunners in the Neurostimulation Devices Market. Companies such as LivaNova PLC, NeuroPace, Inc., Nevro Corporation, NeuroSigma, Inc., Neuronetics, Inc., Synapse Biomedical, Inc., and Integer Holdings Corporation are some of the key innovators in the market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Nevro Corporation, Medtronic PLC, NeuroSigma, Inc., Integer Holdings Corporation, LivaNova PLC, NeuroPace, Inc., Neuronetics, Inc., and Synapse BioMedical, Inc.

Recent strategies deployed in Neurostimulation Devices Market
Partnerships, Collaborations, and Agreements:

May-2020: Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson’s disease, and other neurological disorders.
Oct-2019: NeuroSigma came into partnership with Quick Care Pharmacy, a California-based specialty pharmacy. Following the partnership, the latter company was aimed to sell and distribute the former company’s Monarch eTNS System (Monarch) for the treatment of pediatric ADHD in the United States.
Jun-2019: Neuronetics teamed up with Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. Following the collaboration, Teijin sells NeuroStar Transcranial Magnetic Stimulation (TMS) in Japan.
May-2019: Abbott came into partnership with the US National Institutes of Health (NIH). The partnership was aimed at developing unique insights and driving the application of neurostimulation therapies. The partnership would provide the latter company’s neuroscience research initiative BRAIN access to Abbott’s neuromodulation technologies.
Acquisition and Mergers:
Jan-2020: Medtronic took over Stimgenics, a startup company that has developed a novel spinal cord stimulation waveform. This acquisition enabled the company to expand its business in the SCS Market.
Jun-2019: Boston Scientific acquired Vertiflex, a healthcare company. Through this acquisition, Vertiflex’s spinal cord stimulation and radiofrequency ablation have been added to Boston Scientific’s product portfolio.
Jan-2018: LivaNova PLC acquired ImThera Medical, a company focused on neurostimulation for the treatment of obstructive sleep apnea (“OSA”). The acquisition strengthened its position as a leader in the field of neuromodulation.
Jul-2016: Boston took over Cosman Medical following which Cosman operates under the Boston Scientific Neuromodulation business. Following the acquisition, the company aimed to offer a wide range of spinal cord stimulator (SCS) systems to the patients suffering from chronic pain.
Product Launches and Product Expansions:
Jan-2019: Boston Scientific introduced the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems. The systems feature the Vercise Cartesia Directional Lead. The systems have the technology that enables the physicians in controlling the range, shape, position, and direction of electrical stimulation to treat the symptoms of Parkinson’s disease (PD) through highly-personalized therapy.
Jan-2019: Boston launched WaveWriter Spinal Cord Stimulator (SCS) System in Europe for providing the treatment of chronic pain to people in Europe.
Approvals:
Mar-2020: Symmetry, LivaNova’s vagus nerve stimulation therapy for treatment-resistant depression, got CE Mark in Europe. Symmetry is a small implantable device designed for stimulating the vagus nerve to improve symptoms of depression and quality of life.
Mar-2020: Neuronetics announced that its NeuroStar Advanced Therapy System has been approved by the FDA. This system is used for the treatment of bipolar depression. The system uses transcranial magnetic stimulation (TMS), a noninvasive form of neuromodulation, to stimulate areas of the brain that are underactive in depression.
Mar-2020: NeuroPace received approval from FDA for MRI labeling. The approval was for its RNS systems that are programmed to help people living with seizures who don’t respond to medication. RNS system is the world’s only closed-loop brain-responsive neurostimulation system that helps to prevent seizures at their source. The system comprises of a neurostimulator, leads mounted at the seizure foci, a remote monitor that uploads data, as well as an RNS tablet and patient data system. The data systems help the physicians with viewing data over a secure website which can further be used for personalized therapies.
Jan-2020: Medtronic secured a CE Mark for its Percept PC neurostimulator. It is the only deep brain stimulation (DBS) system launched in the EU with BrainSense technology, which senses and records brain signals while delivering DBS therapy to people with neurological disorders such as Parkinson’s disease.
Jan-2020: Abbott Laboratories got approval from the US Food and Drug Administration (FDA) for its Infinity Deep Brain Stimulation (DBS) system. This system would be used in the treatment of Parkinson’s disease. The system would enable targeting a specific area of the brain known as the internal globus pallidus (GPi) for improving the symptoms of Parkinson’s disease not controlled by medication.
Nov-2019: Nevro Corporation received approval from the FDA for the Senza Omnia Spinal Cord Stimulation (SCS) System. The Omnia system has been designed for delivering Nevro’s proprietary HF10 therapy in addition to all other available SCS frequencies.

Scope of the Study
Market Segmentation:

By Devices
• Spinal Cord Stimulators
• Deep Brain Stimulators
• Sacral Nerve Stimulators
• Vagus Nerve Stimulators and
• Other Devices

By Applications
• Pain Management
• Hearing Loss
• Urinary Incontinence
• Parkinson’s Disease
• Epilepsy and
• Other Applications

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• Abbott Laboratories
• Boston Scientific Corporation
• Nevro Corporation
• Medtronic PLC
• NeuroSigma, Inc.
• Integer Holdings Corporation
• LivaNova PLC
• NeuroPace, Inc.
• Neuronetics, Inc.
• Synapse BioMedical, Inc.

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Neurostimulation Devices Market, by Devices
1.4.2 Global Neurostimulation Devices Market, by Applications
1.4.3 Global Neurostimulation Devices Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis – Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.2.4 Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, Oct – 2020, May) Leading Players
Chapter 4. Global Neurostimulation Devices Market by Devices
4.1 Global Spinal Cord Stimulators Market by Region
4.2 Global Deep Brain Stimulators Market by Region
4.3 Global Sacral Nerve Stimulators Market by Region
4.4 Global Vagus Nerve Stimulators Market by Region
4.5 Global Other Devices Market by Region
Chapter 5. Global Neurostimulation Devices Market by Applications
5.1 Global Pain Management Market by Region
5.2 Global Hearing Loss Market by Region
5.3 Global Urinary Incontinence Market by Region
5.4 Global Parkinson’s Disease Market by Region
5.5 Global Epilepsy Market by Region
5.6 Global Other Applications Market by Region
Chapter 6. Global Neurostimulation Devices Market by Region
6.1 North America Neurostimulation Devices Market
6.1.1 North America Neurostimulation Devices Market by Devices
6.1.1.1 North America Spinal Cord Stimulators Market by Country
6.1.1.2 North America Deep Brain Stimulators Market by Country
6.1.1.3 North America Sacral Nerve Stimulators Market by Country
6.1.1.4 North America Vagus Nerve Stimulators Market by Country
6.1.1.5 North America Other Devices Market by Country
6.1.2 North America Neurostimulation Devices Market by Applications
6.1.2.1 North America Pain Management Market by Country
6.1.2.2 North America Hearing Loss Market by Country
6.1.2.3 North America Urinary Incontinence Market by Country
6.1.2.4 North America Parkinson’s Disease Market by Country
6.1.2.5 North America Epilepsy Market by Country
6.1.2.6 North America Other Applications Market by Country
6.1.3 North America Neurostimulation Devices Market by Country
6.1.3.1 US Neurostimulation Devices Market
6.1.3.1.1 US Neurostimulation Devices Market by Devices
6.1.3.1.2 US Neurostimulation Devices Market by Applications
6.1.3.2 Canada Neurostimulation Devices Market
6.1.3.2.1 Canada Neurostimulation Devices Market by Devices
6.1.3.2.2 Canada Neurostimulation Devices Market by Applications
6.1.3.3 Mexico Neurostimulation Devices Market
6.1.3.3.1 Mexico Neurostimulation Devices Market by Devices
6.1.3.3.2 Mexico Neurostimulation Devices Market by Applications
6.1.3.4 Rest of North America Neurostimulation Devices Market
6.1.3.4.1 Rest of North America Neurostimulation Devices Market by Devices
6.1.3.4.2 Rest of North America Neurostimulation Devices Market by Applications
6.2 Europe Neurostimulation Devices Market
6.2.1 Europe Neurostimulation Devices Market by Devices
6.2.1.1 Europe Spinal Cord Stimulators Market by Country
6.2.1.2 Europe Deep Brain Stimulators Market by Country
6.2.1.3 Europe Sacral Nerve Stimulators Market by Country
6.2.1.4 Europe Vagus Nerve Stimulators Market by Country
6.2.1.5 Europe Other Devices Market by Country
6.2.2 Europe Neurostimulation Devices Market by Applications
6.2.2.1 Europe Pain Management Market by Country
6.2.2.2 Europe Hearing Loss Market by Country
6.2.2.3 Europe Urinary Incontinence Market by Country
6.2.2.4 Europe Parkinson’s Disease Market by Country
6.2.2.5 Europe Epilepsy Market by Country
6.2.2.6 Europe Other Applications Market by Country
6.2.3 Europe Neurostimulation Devices Market by Country
6.2.3.1 Germany Neurostimulation Devices Market
6.2.3.1.1 Germany Neurostimulation Devices Market by Devices
6.2.3.1.2 Germany Neurostimulation Devices Market by Applications
6.2.3.2 UK Neurostimulation Devices Market
6.2.3.2.1 UK Neurostimulation Devices Market by Devices
6.2.3.2.2 UK Neurostimulation Devices Market by Applications
6.2.3.3 France Neurostimulation Devices Market
6.2.3.3.1 France Neurostimulation Devices Market by Devices
6.2.3.3.2 France Neurostimulation Devices Market by Applications
6.2.3.4 Russia Neurostimulation Devices Market
6.2.3.4.1 Russia Neurostimulation Devices Market by Devices
6.2.3.4.2 Russia Neurostimulation Devices Market by Applications
6.2.3.5 Spain Neurostimulation Devices Market
6.2.3.5.1 Spain Neurostimulation Devices Market by Devices
6.2.3.5.2 Spain Neurostimulation Devices Market by Applications
6.2.3.6 Italy Neurostimulation Devices Market
6.2.3.6.1 Italy Neurostimulation Devices Market by Devices
6.2.3.6.2 Italy Neurostimulation Devices Market by Applications
6.2.3.7 Rest of Europe Neurostimulation Devices Market
6.2.3.7.1 Rest of Europe Neurostimulation Devices Market by Devices
6.2.3.7.2 Rest of Europe Neurostimulation Devices Market by Applications
6.3 Asia Pacific Neurostimulation Devices Market
6.3.1 Asia Pacific Neurostimulation Devices Market by Devices
6.3.1.1 Asia Pacific Spinal Cord Stimulators Market by Country
6.3.1.2 Asia Pacific Deep Brain Stimulators Market by Country
6.3.1.3 Asia Pacific Sacral Nerve Stimulators Market by Country
6.3.1.4 Asia Pacific Vagus Nerve Stimulators Market by Country
6.3.1.5 Asia Pacific Other Devices Market by Country
6.3.2 Asia Pacific Neurostimulation Devices Market by Applications
6.3.2.1 Asia Pacific Pain Management Market by Country
6.3.2.2 Asia Pacific Hearing Loss Market by Country
6.3.2.3 Asia Pacific Urinary Incontinence Market by Country
6.3.2.4 Asia Pacific Parkinson’s Disease Market by Country
6.3.2.5 Asia Pacific Epilepsy Market by Country
6.3.2.6 Asia Pacific Other Applications Market by Country
6.3.3 Asia Pacific Neurostimulation Devices Market by Country
6.3.3.1 China Neurostimulation Devices Market
6.3.3.1.1 China Neurostimulation Devices Market by Devices
6.3.3.1.2 China Neurostimulation Devices Market by Applications
6.3.3.2 India Neurostimulation Devices Market
6.3.3.2.1 India Neurostimulation Devices Market by Devices
6.3.3.2.2 India Neurostimulation Devices Market by Applications
6.3.3.3 Japan Neurostimulation Devices Market
6.3.3.3.1 Japan Neurostimulation Devices Market by Devices
6.3.3.3.2 Japan Neurostimulation Devices Market by Applications
6.3.3.4 South Korea Neurostimulation Devices Market
6.3.3.4.1 South Korea Neurostimulation Devices Market by Devices
6.3.3.4.2 South Korea Neurostimulation Devices Market by Applications
6.3.3.5 Singapore Neurostimulation Devices Market
6.3.3.5.1 Singapore Neurostimulation Devices Market by Devices
6.3.3.5.2 Singapore Neurostimulation Devices Market by Applications
6.3.3.6 Malaysia Neurostimulation Devices Market
6.3.3.6.1 Malaysia Neurostimulation Devices Market by Devices
6.3.3.6.2 Malaysia Neurostimulation Devices Market by Applications
6.3.3.7 Rest of Asia Pacific Neurostimulation Devices Market
6.3.3.7.1 Rest of Asia Pacific Neurostimulation Devices Market by Devices
6.3.3.7.2 Rest of Asia Pacific Neurostimulation Devices Market by Applications
6.4 LAMEA Neurostimulation Devices Market
6.4.1 LAMEA Neurostimulation Devices Market by Devices
6.4.1.1 LAMEA Spinal Cord Stimulators Market by Country
6.4.1.2 LAMEA Deep Brain Stimulators Market by Country
6.4.1.3 LAMEA Sacral Nerve Stimulators Market by Country
6.4.1.4 LAMEA Vagus Nerve Stimulators Market by Country
6.4.1.5 LAMEA Other Devices Market by Country
6.4.2 LAMEA Neurostimulation Devices Market by Applications
6.4.2.1 LAMEA Pain Management Market by Country
6.4.2.2 LAMEA Hearing Loss Market by Country
6.4.2.3 LAMEA Urinary Incontinence Market by Country
6.4.2.4 LAMEA Parkinson’s Disease Market by Country
6.4.2.5 LAMEA Epilepsy Market by Country
6.4.2.6 LAMEA Other Applications Market by Country
6.4.3 LAMEA Neurostimulation Devices Market by Country
6.4.3.1 Brazil Neurostimulation Devices Market
6.4.3.1.1 Brazil Neurostimulation Devices Market by Devices
6.4.3.1.2 Brazil Neurostimulation Devices Market by Applications
6.4.3.2 Argentina Neurostimulation Devices Market
6.4.3.2.1 Argentina Neurostimulation Devices Market by Devices
6.4.3.2.2 Argentina Neurostimulation Devices Market by Applications
6.4.3.3 UAE Neurostimulation Devices Market
6.4.3.3.1 UAE Neurostimulation Devices Market by Devices
6.4.3.3.2 UAE Neurostimulation Devices Market by Applications
6.4.3.4 Saudi Arabia Neurostimulation Devices Market
6.4.3.4.1 Saudi Arabia Neurostimulation Devices Market by Devices
6.4.3.4.2 Saudi Arabia Neurostimulation Devices Market by Applications
6.4.3.5 South Africa Neurostimulation Devices Market
6.4.3.5.1 South Africa Neurostimulation Devices Market by Devices
6.4.3.5.2 South Africa Neurostimulation Devices Market by Applications
6.4.3.6 Nigeria Neurostimulation Devices Market
6.4.3.6.1 Nigeria Neurostimulation Devices Market by Devices
6.4.3.6.2 Nigeria Neurostimulation Devices Market by Applications
6.4.3.7 Rest of LAMEA Neurostimulation Devices Market
6.4.3.7.1 Rest of LAMEA Neurostimulation Devices Market by Devices
6.4.3.7.2 Rest of LAMEA Neurostimulation Devices Market by Applications
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals:
7.2 Boston Scientific Corporation
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.2.5.2 Product Launches and Product Expansions:
7.3 Nevro Corporation
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals:
7.4 Medtronic PLC
7.4.1 Company overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Acquisition and Mergers:
7.4.5.3 Product Launches and Product Expansions:
7.4.5.4 Approvals:
7.5 NeuroSigma, Inc.
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Partnerships, Collaborations, and Agreements:
7.6 Integer Holdings Corporation
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 LivaNova PLC
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals:
7.7.5.2 Acquisition and Mergers:
7.8 NeuroPace, Inc.
7.8.1 Company Overview
7.8.2 Recent strategies and developments:
7.8.2.1 Approvals:
7.8.2.2 Product Launches and Product Expansions:
7.9 Neuronetics, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals:
7.1 Synapse BioMedical, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Approvals:



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経刺激装置の世界市場2020-2026:装置別(脊髄刺激装置、脳深部刺激装置、仙骨神経刺激装置、迷走神経刺激装置、その他)、用途別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆